(Q37211244)

English

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

scientific article published on 19 September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

quality of life

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

author name string

Jean-Marie Rakic

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Anita Leys

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Heidi Brié

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Kris Denhaerynck

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Christy Pacheco

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Stefaan Vancayzeele

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Christine Hermans

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Karen Macdonald

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ivo Abraham

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

19 September 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Clinical Ophthalmology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1849-1858

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 September 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Psychological and cognitive determinants of vision function in age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Global data on visual impairment in the year 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Age-related macular degeneration and quality of life: how to interpret a research paper in health-related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Prevalence of age-related macular degeneration in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

The Health Utilities Index (HUI): concepts, measurement properties and applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Quality of life with macular degeneration: perceptions of patients, clinicians, and community members.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Development of the 25-item National Eye Institute Visual Function Questionnaire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

6 September 2017

Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

26 June 2018

Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

3 September 2018

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

3 September 2018

Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3788820

3 September 2018

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/24092964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24092964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age-related macular degeneration is the leading cause of blindness...

1 reference

https://pubmed.ncbi.nlm.nih.gov/24092964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/OPTH.S49385

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37211244&oldid=2229650116"